Published in In Vivo, October 2018
Authors: Dr. Swarna Mehrotra, Dr. Oded Ben-Joseph and Dr. Ellen Baron
There is a unique phenomenon being realized in immuno-oncology deal-making compared with other segments in the life sciences sector – an apparent uncoupling between risk and return on invested capital, as early assets provide similar liquidity to more mature assets. Unicorn transactions have emerged in the IO sector, as well as never seen before partnerships, financing deals that regularly hit above $200 million, and multibillion-dollar acquisitions and IPO valuations. The market is optimizing multiple paths to liquidity at all stages of development and experiencing a shortening in time to exit, which is further propelling investor appetite.
So what? As IO drugs demonstrate robust clinical potential and early movers reap market rewards, the segment continues to attract significant interest from the investor community as well as pharma and biotech players, triggering highly competitive behavior and intense transactional activity. IO may be the perfect storm for venture returns. It represents a radical change from traditional cytotoxic drugs, the capital markets are booming, and traditionally slow regulators have catalyzed meaningful new product approvals based on unprecedented clinical data. This is driving VCs flush with cash to engorge new IO market entrants with capital to hit value-inflecting milestones. Coupled with large players jumping at early M&As, biotech companies are enjoying a high probability to exit early.
The question that remains: are we in the midst of a transformational inflection point in scientific progress leading to meaningful improvements in clinical outcomes or are we witnessing irrational exuberance by investors and strategic players leading to unduly escalated asset values? Time will tell.
June 23, 2021, Reston, VA Outcome Capital, an investment banking firm that serves middle market growth companies in aerospace, defense and government services, technology, and life sciences, is pleased to announce that Nova Technologies (“Nova” or the “Company”) has received an equity investment from Slate Capital Group, a private equity firm based in Baltimore, MD, […]Read More
June 17, 2021 09:40 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Outcome Capital, a specialized advisory and investment banking firm that serves middle market companies in the life science and technology segments, today announced that Veranex, a newly formed concept-to-commercialization service provider dedicated to the medtech industry, has acquired Boston Healthcare Associates (BHA), a global strategy consulting […]Read More
Outcome Capital Life Science Market Pulse June 2021 Click to view our LifeSciences Pulse NewsletterDownload